ReviewJournal of hematology & oncology2010
Angiogenesis inhibitors in the treatment of prostate cancer.
Review in Journal of hematology & oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 67 citations in OpenAlex.
- A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.European journal of cancer (Oxford, England : 1990) · 2015Trial
- Potential Therapeutic Actions of Flavonoids Present in Propolis That Modulate Vascular Endothelial Growth Factor Signaling to Regulate Angiogenesis.Phytotherapy research : PTR · 2025Review
- Transcriptomic analysis of the anti-tumor effects of leflunomide in prolactinoma.Scientific reports · 2025Article
- Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001).Pharmaceutics · 2025Article
- Review
- Anoikis in prostate cancer bone metastasis gene signatures and therapeutic implications.Frontiers in oncology · 2024Article
- Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties.Pharmaceutics · 2022Review
- Review
- Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening.Reviews of physiology, biochemistry and pharmacology · 2021Review
- Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies.Frontiers in oncology · 2021Review
- Angiogenesis Inhibition in Prostate Cancer: An Update.Cancers · 2020Review
- Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.International journal of molecular sciences · 2020Article
- Leflunomide Inhibits Proliferation and Induces Apoptosis via Suppressing Autophagy and PI3K/Akt Signaling Pathway in Human Bladder Cancer Cells.Drug design, development and therapy · 2020Article
- The αvβ6 integrin in cancer cell-derived small extracellular vesicles enhances angiogenesis.Journal of extracellular vesicles · 2020Article
- Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.Oncotarget · 2016Article
- Vasculogenic Mimicry in Prostate Cancer: The Roles of EphA2 and PI3K.Journal of Cancer · 2016Article
- Endothelial Caveolin-1 regulates the radiation response of epithelial prostate tumors.Oncogenesis · 2015Article
- Aberrant BAF57 signaling facilitates prometastatic phenotypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Severity of hematuria effects resolution in patients treated with hyperbaric oxygen therapy for radiation-induced hematuria.Urologia internationalis · 2013Article
- Antiangiogenic therapy for cancer: an update.Pharmacotherapy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer remains a significant public health problem, with limited therapeutic options in the setting of castrate-resistant metastatic disease. Angiogenesis inhibition is a relatively novel antineoplastic approach, which targets the reliance of tumor growth on the formation of new blood vessels. This strategy has been used successfully in other solid tumor types, with the FDA approval of anti-angiogenic agents in breast, lung, colon, brain, and kidney cancer. The application of anti-angiogenic therapy to prostate cancer is reviewed in this article, with attention to efficacy and toxicity results from several classes of anti-angiogenic agents. Ultimately, the fate of anti-angiogenic agents in prostate cancer rests on the eagerly anticipated results of several key phase III studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.